Lexington's Shire said yesterday it will pay $5.2 billion to acquire NPS Pharmaceuticals Inc., which specializes in drugs for rare conditions.
The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. The best-selling medications of the Irish drugmaker — which bases its U.S. operations in Lexington — currently include the attention deficit disorder drugs Vyvanse and Adderall XR.
Shire Chief Executive Officer Flemming Ornskov said he would keep looking for more deals to grow the company into a biotech powerhouse.
"This is about growth and rare diseases, and it fits hand in glove with our strategy and our franchise," Ornskov said.
NPS currently has one drug on the market in the U.S. and Europe: Gattex, which is used to treat short bowel syndrome, a potentially life-threatening chronic condition that prevents patients from absorbing nutrients from food. The drug had sales of $67.9 million for the first nine months of 2014.
NPS is awaiting approval from the Food and Drug Administration for a second drug, Natpara, which is designed to treat a rare condition called hypoparathyroidism. The FDA is slated to decide on the Natpara application by Jan. 24.
The takeover continues the breakneck pace of deal-making in 2014 in the pharmaceuticals sector, as companies jockey for promising assets amid a wave of new drugs emerging from research laboratories.
Also yesterday, Cambridge-based Biogen Idec announced that it has agreed to acquire U.K.-based Convergence Pharmaceuticals. Biogen Idec plans to leverage Convergence's expertise in chronic pain research.
"Neuropathic pain is an area of significant unmet need and represents a natural complement to our current neurology portfolio," said Douglas Williams, executive vice president of research and development at Biogen Idec. "The team at Convergence has pioneered some of the most innovative science in pain management. We believe their industry-leading talent, capabilities and pipeline of candidates, starting with CNV1014802, will provide a strong foundation upon which to expand our neuropathic pain portfolio."
Under the terms of the deal, Biogen Idec will pay Convergence shareholders an upfront payment of $200 million. Convergence shareholders are eligible to receive additional payments up to $475 million contingent on future milestones. Convergence will continue to operate out of Cambridge, U.K.
Anda sedang membaca artikel tentang
Area pharmaceutical companies make acquisitions
Dengan url
http://sedangapasaja.blogspot.com/2015/01/area-pharmaceutical-companies-make.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Area pharmaceutical companies make acquisitions
namun jangan lupa untuk meletakkan link
Area pharmaceutical companies make acquisitions
sebagai sumbernya
0 komentar:
Posting Komentar